European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - 37th Congress
Drugs of the Future
; 46(12):1037-1039, 2021.
Article
in English
| EMBASE | ID: covidwho-1854921
ABSTRACT
This year's ECTRIMS brought scientists and specialists together to discuss developments in multiple sclerosis (MS), including how to define and monitor disease progression, imaging pathology, and, of course, the impact of the COVID-19 pandemic on MS patient care.
NCT04115488; act 01; bn 201; cnm au8; elezanumab; natalizumab; neuroprotective agent; ocrelizumab; opicinumab; recombinant gamma interferon; SARS-CoV-2 vaccine; tozinameran; unclassified drug; area under the curve; conference paper; drug clearance; drug efficacy; drug half life; drug safety; drug tolerability; Expanded Disability Status Scale; human; maximum concentration; multiple sclerosis; nanocatalyst; optic neuritis; phase 1 clinical trial (topic); phase 3 clinical trial (topic); randomized controlled trial (topic); treatment outcome; comirnaty; tysabri
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Drugs of the Future
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS